Effect of different dialysis modalities on microinflammatory status and endothelial damage

Clin J Am Soc Nephrol. 2010 Feb;5(2):227-34. doi: 10.2215/CJN.03260509. Epub 2010 Jan 7.

Abstract

Background and objectives: We studied the relationship between microinflammation and endothelial damage in chronic kidney disease (CKD) patients on different dialysis modalities.

Design, setting, participants, & measurements: Four groups of CKD stage 5 patients were studied: 1) 14 nondialysis CKD patients (CKD-NonD); 2) 15 hemodialysis patients (HD); 3) 12 peritoneal dialysis patients with residual renal function >1 ml/min (PD-RRF >1); and 4) 13 peritoneal dialysis patients with residual renal function <or=1 ml/min (PD-RRF <or=1). Ten healthy subjects served as controls. CD14(+)CD16(+) cells and apoptotic endothelial microparticles (EMPs) were measured by flow cytometry. Serum vascular endothelial growth factor (VEGF) was measured by ELISA.

Results: CKD-NonD and HD patients had a higher percentage of CD14(+)CD16(+) monocytes than PD groups and controls. CD14(+)CD16(+) was similar in the PD groups, regardless of their RRF, and controls. The four uremic groups displayed a marked increase in apoptotic EMPs and VEGF compared with controls. Apoptotic EMPs and VEGF were significantly higher in HD patients than in CKD-NonD and both PD groups. However, there were no significant differences between CKD-NonD and the two PD groups. There was a correlation between CD14(+)CD16(+) and endothelial damage in CKD-NonD and HD patients, but not in PD and controls.

Conclusions: There was an increase in CD14(+)CD16(+) only in CKD-NonD and HD patients. In these patients, there was a relationship between increased CD14(+)CD16(+) and endothelial damage. These results strongly suggest that other factors unrelated to the microinflammatory status mediated by CD14(+)CD16(+) are promoting the endothelial damage in PD, regardless of their RRF.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Apoptosis*
  • Biomarkers / blood
  • Cell-Derived Microparticles / immunology
  • Cell-Derived Microparticles / pathology*
  • Chronic Disease
  • Endothelium, Vascular / immunology
  • Endothelium, Vascular / pathology*
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Flow Cytometry
  • GPI-Linked Proteins
  • Humans
  • Inflammation / immunology*
  • Inflammation / pathology
  • Inflammation Mediators / blood*
  • Kidney Diseases / immunology
  • Kidney Diseases / pathology
  • Kidney Diseases / therapy*
  • Lipopolysaccharide Receptors / blood
  • Male
  • Middle Aged
  • Monocytes / immunology*
  • Peritoneal Dialysis* / adverse effects
  • Receptors, IgG / blood
  • Renal Dialysis* / adverse effects
  • Risk Factors
  • Vascular Endothelial Growth Factor A / blood

Substances

  • Biomarkers
  • FCGR3B protein, human
  • GPI-Linked Proteins
  • Inflammation Mediators
  • Lipopolysaccharide Receptors
  • Receptors, IgG
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A